Aurinia Pharmaceuticals (AUPH) Projected to Post Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Free Report) (TSE:AUP) will likely be posting its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.04 per share and revenue of $59.94 million for the quarter.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $7.79 on Tuesday. The company has a 50-day simple moving average of $8.47 and a 200-day simple moving average of $7.66. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -51.93 and a beta of 1.22.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, February 10th.

Get Our Latest Report on AUPH

About Aurinia Pharmaceuticals

(Get Free Report)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Further Reading

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.